Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Regeneron will also get a tax break on about $50 million of the renovation costs at the site, with exemptions of up to about $4.19 million in state and local sales taxes, according to IDA documents.
In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [23] [24] Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the ...
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
Regeneron CEO Dr. Leonard Schleifer tells ‘America’s Newsroom’ the company is trying to get expanded emergency use authorization from the FDA so others can access the treatment.
By Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann ...